Tibi Pharma AB

ABActive

Org 5594537648Danderydsvägen 146, 182 36 DanderydWholesale of pharmaceutical and medical goods· NACE 4646Est. 2023 · 2 years old0 employees

Overview

Tibi Pharma AB is a Swedish AB based in Danderyd, operating in the Wholesale of pharmaceutical and medical goods sector. Incorporated in 2023, the company has 0 employees and reported revenue of SEK 1.6m in its latest annual filing.

Revenue 2025

1.6M SEK

+151% vs 2024

EBITDA margin

2.4 %

+147% vs 2024

Net profit 2025

0M SEK

+147% vs 2024

Key ratios

See full ratios →

64.1 %

Strong

Among the 40% highest rated companies in the industry

20242025

2.8×

Average

Around the average of companies in the same industry

20242025

4.5 %

Average

Around the average of companies in the same industry

20242025

EBITDA — year on year

SEK thousands

Key figures

Annual report 2025

Revenue	1.6M SEK	+151%
EBITDA	0M SEK	+147%
Net profit	0M SEK	+147%
Total assets	0.9M SEK	+256%
Equity	0.6M SEK	+156%
Employees	0	—

Contact

Address

Danderydsvägen 146, 182 36 Danderyd

finance@tibipharma.se

Risika for professionals

Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.

Visit risika.com

Financial development

In its most recent annual report (2025), Tibi Pharma AB reported revenue of SEK 1.6m, an increase of 151% on the year before. The figures on this page draw on 2 annual filings covering 2024 to 2025. The bottom line showed a net profit of SEK 39.3k, and the EBITDA margin stood at 2.4%.

At the end of 2025, equity financed 64.1% of the balance sheet, and current assets covered short-term debt 2.8 times.

Financials

Revenue

SEK thousands

EBITDA

SEK thousands

Income statement

SEK thousands

Item	2025	2024
Revenue	1,598	637
Staff expenses	-0	—
EBITDA	39	-83
Depreciation & amort.	-0	-0
EBIT	39	-83
Net financials	0	—
Profit before tax	39	-83
Tax	-0	-0
Net profit	39	-83

Get a credit rating – not just the numbers

Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.

See the credit rating

Balance sheet

SEK thousands

Item	2025	2024
Total assets	868	244
Equity	556	217
Long-term debt	0	0
Short-term debt	311	27
Total debt	311	27

Financial ratios

5-year trend

EBITDA margin

2.4 %

20242025

Equity ratio

64.1 %

Strong

Among the 40% highest rated companies in the industry

20242025

Return on equity

7.1 %

Average

Around the average of companies in the same industry

20242025

Net profit margin

2.5 %

Average

Around the average of companies in the same industry

20242025

Asset turnover

1.84×

Average

Around the average of companies in the same industry

20242025

Debt / equity

0.56×

Strong

Among the 40% highest rated companies in the industry

20242025

Sector performance

27 of 28 ratios graded

28 financial ratios from the latest filing, each graded against companies in the same industry.

Profitability

Gross marginVery weak

Among the 10% lowest rated companies in the industry

The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.

Operating marginAverage

Around the average of companies in the same industry

EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.

Net profit marginAverage

Around the average of companies in the same industry

The profit for the year as a share of revenue — the company's ability to turn revenue into profit.

Return on equity (ROE)Average

Around the average of companies in the same industry

Net profit as a percentage of equity — the return the owners earned on their invested capital this year.

Return on assets (ROA)Average

Around the average of companies in the same industry

Net profit as a percentage of total assets — the return generated on the capital employed.

Return on net assets (RONA)Average

Around the average of companies in the same industry

Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.

Basic earning power (BEP)Average

Around the average of companies in the same industry

EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.

Capacity ratioVery strong

Among the 10% highest rated companies in the industry

Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.

Liquidity

Current ratioAverage

Around the average of companies in the same industry

Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.

Quick ratioStrong

Among the 30% highest rated companies in the industry

Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.

Cash ratioAverage

Around the average of companies in the same industry

Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.

Current assets to equityAverage

Around the average of companies in the same industry

Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.

Fixed assets to long-term capitalStrong

Among the 30% highest rated companies in the industry

Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.

Cash conversion ratioWeak

Among the 40% lowest rated companies in the industry

Cash flow relative to profit — the ability to convert reported profits into accessible cash.

Debt & solvency

Solidity ratioStrong

Among the 40% highest rated companies in the industry

Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.

Debt ratioStrong

Among the 40% highest rated companies in the industry

Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.

Debt to equityStrong

Among the 40% highest rated companies in the industry

Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.

Liabilities to equityStrong

Among the 40% highest rated companies in the industry

Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.

Income to debtStrong

Among the 40% highest rated companies in the industry

Profit relative to debt — the ability to create earnings while operating with debt.

EBITDA to debtAverage

Around the average of companies in the same industry

EBITDA relative to debt — how much operating earnings are available to service the debt.

Interest rate on debtVery strong

Among the 10% highest rated companies in the industry

Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.

Interest marginStrong

Among the 40% highest rated companies in the industry

The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.

Interest coverageNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The ability to pay the interest on the company's debt out of its earnings.

Efficiency & development

Asset turnoverAverage

Around the average of companies in the same industry

Revenue relative to total assets — the ability to generate revenue from the asset base.

Inventory turnoverWeak

Among the 30% lowest rated companies in the industry

Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.

Equity to contributed capitalStrong

Among the 30% highest rated companies in the industry

Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.

One-year change in equityVery strong

Among the 10% highest rated companies in the industry

The size of this year's increase or decrease in the company's equity.

One-year change in debtVery weak

Among the 10% lowest rated companies in the industry

The size of this year's increase or decrease in the company's debt.

Annual reports & filings

Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-10-01 – 2024-12-31
View PDF

People & ownership

Management

Actively employed in the business

Name	Role	Member since
Current (2)
AM Anna Maria Andersson Audit	Audit	2023
SR Shan Rehman Chief Executive Officer	Chief Executive Officer	2023

Board of directors

Non-executive oversight

Name	Role	Member since
Current (2)
HM Helena Maria Westermark Board of Directors	Board of Directors	2023
SR Shan Rehman Deputy Board Member	Deputy Board Member	2023

Shareholders

Active legal owners

No shareholder data available.

One in three Danish companies experiences fraud

Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.

See the fraud module

Related companies

Company hierarchy

No registered parent or subsidiaries

Board network connections

Board members of Tibi Pharma AB also hold positions in 134 other companies.

Person	Role here	Other companies
Anna Maria Andersson	Audit	132 companiesMany roles
Shan Rehman	Chief Executive Officer	1 company
Helena Maria Westermark	Board of Directors	1 company

Frequently asked questions

What is the Org number of Tibi Pharma AB?

Tibi Pharma AB is registered with Bolagsverket / SCB under Org 5594537648.

What is the revenue of Tibi Pharma AB?

Tibi Pharma AB reported revenue of SEK 1.6m in 2025.

Who is the CEO of Tibi Pharma AB?

Shan Rehman is the CEO of Tibi Pharma AB.

Where is Tibi Pharma AB headquartered?

Tibi Pharma AB's registered address is Danderydsvägen 146.